UNSPSC 51351912: Ulipristal acetate

This classification denotes an anti-progestin with the molecular formula C30H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YF7V70N02B. European Medicines Agency schedules ulipristal acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30470. The term ulipristal acetate is a United States Adopted Name designation. As of Q4 2014, ULIPRISTAL ACETATE remains the US FDA Preferred Term for this commodity. Ulipristal acetate bears US NLM identifiers UMLS ID C2723461 and NCI Concept Code C91057.

SMILES: CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)OC(=O)C.

UNSPSC 51351912 Ulipristal acetate, a Commodity code, encompasses pharmaceutical products and active ingredients supplied through state and local cooperative purchasing agreements. State and local governments procure ulipristal acetate and related generic pharmaceuticals as part of broader multi-source drug procurement vehicles that serve health departments, correctional facilities, public hospitals, and other state and local healthcare delivery systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body in recent activity under this code, using cooperative vehicles to aggregate demand across participating state and local facilities in multiple states including Oregon. Vendors supplying under the code must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with authorized wholesale distributors (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and carry comprehensive insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability per occurrence.

MMCAP's Request for Proposal S1070000015802 for Generic Multi Source Pharmaceuticals and Over the Counter Products, posted January 20, 2026, with responses due March 26, 2026, is the primary recent opportunity under this code. The solicitation requires manufacturers to supply detailed product information including NDC codes, SKUs, and packaging configurations, with pricing evaluation weighted 75 percent on competitiveness and 10 percent on fixed pricing for the two-year contract term (with optional extensions through June 30, 2028). All products must be available in the marketplace by May 15, 2026, and awarded vendors will be provided to authorized wholesalers for distribution across state and local health systems. Vendors must comply with FDA requirements, maintain expiration dates of at least one year from manufacture with a six-month minimum shelf life, and accept a 3 percent administrative fee on all contract purchases; the RFP does not identify specific set-aside designations or restrictions limiting responses to particular business classifications.